Susquehanna International Group, LLP Arcus Biosciences, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $325,822 - $428,638	23,800 Added 38.39%	85,800 $1.31 Million
Q2 2024 Aug 15, 2024	SELL	$14.59 - $18.48 $554,420 - $702,240	-38,000 Reduced 38.0%	62,000 $944,000
Q1 2024 May 07, 2024	SELL	$14.83 - $20.18 $44,490 - $60,540	-3,000 Reduced 2.91%	100,000 $1.89 Million
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $2.91 Million - $4.25 Million	-216,600 Reduced 67.77%	103,000 $1.97 Million
Q3 2023 Nov 14, 2023	BUY	$17.62 - $23.54 $35,240 - $47,080	2,000 Added 0.63%	319,600 $5.74 Million
Q2 2023 Aug 11, 2023	BUY	$16.97 - $22.03 $4.15 Million - $5.39 Million	244,500 Added 334.47%	317,600 $6.45 Million
Q1 2023 May 16, 2023	SELL	$15.96 - $23.15 $1.7 Million - $2.47 Million	-106,500 Reduced 59.3%	73,100 $1.33 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $1.1 Million - $2 Million	56,000 Added 45.31%	179,600 $3.71 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $587,719 - $760,771	-25,300 Reduced 16.99%	123,600 $3.23 Million

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.3B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.